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ABSTRAK 
Kanser payudara adalah salah satu daripada penyumbang terbesar dalam kalangan 
penyakit tidak berjangkit di seluruh dunia. Sehingga kini, banyak bukti menunjukkan 
bahawa rintangan terhadap apoptosis oleh sel-sel kanser dan eferositosis yang tidak 
cekap oleh sel-sel fagositik menyebabkan perkembangan penyakit lain dalam kalangan 
pesakit kanser, seperti penyakit autoimun. Kajian terdahulu menunjukkan bahawa 
ekstrak Centella asiatica (C. asiatica) menyebabkan apoptosis kepada sel kanser tetapi 
kajian mengenai eferositosis terhadap sel-sel kanser amatlah terhad. C. asiatica 
mempunyai potensi dalam menjadi rawatan alternatif untuk mendorong apoptosis dan 
eferositosis oleh sel-sel fagositik dalam pesakit kanser. Aktiviti anti-proliferatif ekstrak 
metanol C. asiatica (MECA) terhadap sel kanser payudara (MCF-7) diperolehi dengan 
menjalankan ujian metilina biru (MBA). Dalam kaedah ini, DMSO berfungsi sebagai 
kawalan negatif manakala tamoxifen berfungsi sebagai kawalan positif. Selepas itu, 
mod kematian sel dalam sel-sel yang dirawat MECA ditentukan oleh pewarnaan 
Hoechst 33342 dan selanjutnya disiasat oleh analisis aliran sitometri. Penemuan MBA 
menunjukkan bahawa MECA adalah sitotoksik kepada MCF-7, namun sebaliknya, ia 
tidak toksik kepada sel normal (NIH3T3). Di samping itu, MCF-7 yang dirawat dengan 
MECA mengalami peningkatan apoptosis yang ditunjukkan oleh pendarfluor yang lebih 
cerah, perubahan morfologi nuklear dan pemecahan DNA yang diperhatikan melalui 
pewarnaan Hoechst. Untuk mengkaji aktiviti eferositosis oleh makrofaj (J774A.1), sel 
MCF-7 telah dikultur bersama sel J774A.1 dengan nisbah kepanjangan jangkitan (MOI) 
1: 2. Selepas rawatan dengan MECA, data aliran sitometri menunjukkan peningkatan 
ketara sel-sel apoptosis yang lewat disebabkan oleh apoptosis J774A.1 selepas 
memakan sel-sel MCF-7. Kesimpulannya, MECA dapat meningkatkan aktiviti 
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apoptosis dan eferositosis dalam sel MCF-7, dengan itu ia dicadangkan sebagai rawatan 
alternatif yang bersesuaian untuk kanser payudara. 
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ABSTRACT 
Breast cancer is one of the major contributions in non-communicable diseases 
worldwide. To date, much evidence has shown that resistance to apoptosis by cancer 
cells and inefficient efferocytosis by phagocytic cells in cancer patients foster the 
development of other diseases in cancer patients, such as autoimmune diseases. 
Previous studies have shown that Centella asiatica (C. asiatica) extract induced 
apoptosis in cancer cell line but there was a lack of study regarding efferocytosis against 
cancer cells. C. asiatica has the potential to be an alternative treatment to induce 
apoptosis and efferocytosis by phagocytic cells in cancer patients. The anti-proliferative 
activity of methanol extract of C. asiatica (MECA) against breast cancer cell line 
(MCF-7) was obtained by performing methylene blue assay (MBA). In this method, 
DMSO served as a negative control while tamoxifen served as a positive control. After 
that, the mode of cell death in MECA-treated cells was determined by Hoechst 33342 
staining and was further investigated by flow cytometry analysis. The findings on the 
MBA suggested that MECA was cytotoxic on MCF-7 and not toxic on normal cells 
(NIH3T3). Furthermore, MCF-7 treated with MECA undergone increased apoptosis 
indicated by brighter fluorescence, alteration of nuclear morphology and DNA 
fragmentation observed in Hoechst staining. To study efferocytosis activity by 
macrophages (J774A.1), MCF-7 cells were cultivated in J774A.1 cells with multiplicity 
of infection (MOI) of 1:2. After treatment with MECA, flow cytometry data showed a 
significant increase of late apoptotic cells due to apoptosis of J774A.1 after engulfing 
MCF-7 cells. In conclusion, MECA was able to improve the activities of apoptosis and 
efferocytosis in MCF-7 cells, thus suggesting a promising alternative treatment for 
breast cancer. 
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CHAPTER 1 
INTRODUCTION 
1.1 Study background 
Cancer has dominated and remained as a major contributor to mortality in society 
worldwide and one of the major contributors is breast cancer (Ab Manan et al., 2016). 
Today, the increase in the number of deaths caused by breast cancer is higher than 
coronary heart disease (CHD) and stroke (Ferlay et al., 2015). This is because, breast 
cancer is very complicated and it is a heterogeneous disease that is closely related to 
pathology, biochemistry and etiology, making breast cancer the leading cause of death 
worldwide (Hoshyar et al., 2015). The increase in breast cancer statistics is caused by 
several biological capabilities including sustaining proliferative signaling, evading 
growth suppressors, resisting cell death (apoptosis), enabling replicative immortality, 
inducing angiogenesis, and activating invasion and metastasis (Hanahan and Weinberg, 
2011). 
Nowadays, there are several treatments for breast cancer, which is it usually requires a 
multimodal approach such as medical, surgical and radiological. However, all these 
approaches are impossible to cure breast cancer (Hoshyar et al., 2015). Besides that, 
recent treatments in breast cancer including chemotherapy, hormonal treatment and 
targeted therapy are sophisticated, expensive, ineffective as well as they are not widely 
available in certain countries (Hoshyar et al., 2015).  
Among the treatments mentioned before, chemotherapy is the most preferred option 
because it is most convenient and involves the selection of several medications to 
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control the critical stage of malignant tissue and metastatic diseases (Fernando and 
Jones, 2015). Despite the success of chemotherapy treatments in dealing with cancer 
problems, conventional drugs that commonly used in treating breast cancer such as 
tamoxifen, usually have serious side effects especially in developing kidney failure 
(Mahassni and Al-Reemi, 2013). Moreover, chemotherapy medications also can exert 
toxic effects on normal cell division, for example bone marrow and mucus membrane 
(Fernando and Jones, 2015). In addition, chemotherapy medications will also cause 
adverse effects to some of the organ systems and may also cause resistance to 
medications that currently remain the main obstacle to achieve benefits and success in 
clinical treatment (Mahassni and Al-Reemi, 2013). 
Due to this matter, many researchers seek to find the best treatment for anti-cancer 
agents. In this quest, natural products have attracted many researchers such as 
pharmacologists and biochemists in producing potentially therapeutic agents in treating 
cancer (Baker et al., 2007). The use of natural products is becoming popular today as 
most of them have been optimized to become drug-like molecules and remain the best 
source of drugs (Newman and Cragg, 2012). Historically, extraordinary story of the 
discovery and use of natural products has proven that it affects the advancement in 
biology and the discovery of drug therapy (Shen, 2015). Therefore, natural products are 
among the consistent products and sources of success in medicine as it has become an 
important source in contributing to the basic needs of everyday life. The use of natural 
products is not limited to food sources but it is more than that because it plays an 
important role in traditional medicine in treating several diseases (Thomas et al., 2001).  
Over the past few decades, the use of natural products as an alternative medicine has 
been detected (Thomas et al., 2001) and today, most research focuses on herbs and 
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aromatherapy products, where some of them have proven therapeutic to cancer (Mans et 
al., 2000; Yin et al., 2013). In this current study, natural herbs known as Centella 
asiatica (C. asiatica) has been selected because it can be used extensively, especially in 
traditional treatments worldwide and it has been claimed to possess anti-cancer 
properties (Jamil et al., 2007). Furthermore, there are some scientific evidences that C. 
asiatica has been used since prehistoric of Ayurveda and aborigines as therapeutic 
agents including wound healing, rheumatoid arthritis, aging, fertility and as well as an 
anti-cancer remedy (Kim et al., 2011a). In Malaysia, C. asiatica is also widely practiced 
and eaten freshly as “ulam” among Malaysians especially in women (Reihani and 
Azhar, 2012).  
Previous study conducted by Michael (2016) has shown that C. asiatica can stimulate 
innate immune system by producing high anti-inflammatory cytokines and toxic 
mediators such as nitric oxide in macrophage. However, there was no study conducted 
to investigate the clearance of apoptotic materials in cancer cells. As apoptosis is one of 
the hallmarks in developing cancer, impaired of apoptosis can lead to a main obstacle to 
effective treatment (Adams and Cory, 2007). Inefficient clearance of apoptotic materials 
can lead to abnormal immune responses including accumulation of autoantigens in 
tissues that cause several diseases such as chronic inflammatory diseases, autoimmune 
diseases and developmental abnormalities (Yoon et al., 2015). Therefore, this present 
study is carried out to investigate the effectiveness of C. asiatica in triggering clearance 
of apoptotic cells by macrophage.  
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1.2 Objectives of the study 
1.2.1 General objectives 
The objective of this study is to determine the ability of methanol extract of C. asiatica 
(MECA) on apoptosis activity of MCF-7 and efferocytosis in J774A.1 macrophage.  
1.2.2 Specific objectives 
a) To determine the cytotoxicity activity of the MECA-treated against MCF-7 and 
NIH3T3 cell lines by using methylene blue assay (MBA) technique. 
b) To determine the apoptotic activities of the MECA-stimulated cells by using 
Hoechst staining. 
c) To determine the clearance of apoptotic materials stimulated with MECA against 
MCF-7 cell line by J774A.1 macrophage through flow cytometry. 
  
	 5 
1.3 Hypothesis 
MECA stimulates the ability of apoptosis activities in treated cell lines and also 
stimulates J774A.1 macrophage to clear the apoptotic materials of the MCF-7 treated 
cancer cells. It is also induced macrophage apoptosis in J774A.1.  
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CHAPTER 2 
LITERATURE REVIEW 
2.1 Cancer 
Cancer is an uncontrolled proliferation of abnormal cells beyond their normal 
boundaries, which it can metastasize to the adjacent parts of the body and other organs 
(WHO, 2017a). There are several factors that caused cancer; internally and externally. 
The internal factors include inherited mutations, hormones, immune system conditions 
and mutations that occur from metabolism (Rieger, 2004). However, both internal and 
external factors can act and interact with each other to promote carcinogenesis. For 
example, external factors such as physical, chemical and biological carcinogens can 
alter person’s genetic factor (Rieger, 2004).  
There are two types of tumor classifications; benign and malignant tumor (Table 2.1). A 
benign tumor (primary cancer) is not a cancerous tumor, which it does not invade its 
surrounding tissue or spread around the body. Primary cancer is a tumor mass that 
presents at the site of initial conversion of a normal cell to a tumor cell (Oppenheimer, 
2006). Meanwhile, a malignant tumor is a tumor that may invade its surrounding tissue 
or spread around the body. In some cases, benign tumor may cause the development of 
metastasis (secondary cancer) if it not treated (Kangawa et al., 2015). Cancer cells that 
spread to areas that is indirectly adjacent to the primary cancer is called as metastasis 
through invasion of blood or lymph vessels or by penetrating the cancer cells into the 
body cavity or spaces of surrounding organs (Kitamura et al., 2015).  
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Table 2.1: Differences between benign and malignant tumors (Oppenheimer, 2006). 
 Benign Malignant 
Cells Relatively normal and 
mature. 
Little resembles to normal, poorly 
differentiated, atypical in size and 
shape, non-uniform and immature. 
Growth Slow and restricted. Non-
invasive of surrounding 
tissue, expansive and 
pushing aside normal tissue. 
Rapid and unrestricted. Invasive of 
surrounding tissue. 
Recurrence Rare Frequent 
Spread Localized and capsulated. Metastasize via blood and lymph 
stream. 
Threat 
host 
Prognosis favorable. The 
effects are depending on the 
size and location. It may 
cause pressure on vital 
organs and obstruct a 
passageway, which is 
usually corrected by surgical 
excision of neoplasms.  
Threatens life due to its local vicious 
proliferation and formation of 
secondary neoplasms in other 
structures. Prognosis more favorable 
with early diagnosis and treatment 
when cells show less departure from 
the normal and there is no 
metastasis. 
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According to Oppenheimer (2006), there are several stages of metastasis such as 
detachment of cells from the primary tumor, migration of tumor cells, penetration 
(invasion) of these cells into lymph vessels or blood vessels and dissemination of the 
cells or cell clusters to distant areas. Other than that, lodging of tumor cells in blood 
vessels of distant organs, invasion of tumor cells through the vessel walls and into the 
tissue of secondary sites and growth of secondary tumor at the secondary sites are also 
can be considered as the stage of metastasis.  
2.1.1 Breast cancer 
Breast cancer occurs when abnormal cells in the breast proliferates out of control in one 
or both breasts and invade nearby tissues thus form a mass called as malignant tumor. 
The malignant tumor or also known as cancerous tumor can metastasize to the lymph 
nodes and other parts of the body (ACS, 2016). Majorly, breast cancer is caused by the 
mutation in genes, which are present in nucleus of all cells in body known as BRCA1 
and BRCA2 (Majeed et al., 2014). 
2.1.2 Prevalence of breast cancer 
Breast cancer is one of the most important undeniable non-communicable disease 
worldwide. In 2008, about 1.38 million new breast cancer cases were diagnosed with 
almost half of all breast cancer cases. Previous study by Lancet (2009) and Shulman et 
al. (2010) stated that, an estimated 1.7 million women will be diagnosed with breast 
cancer in 2020.  
The percentage of breast cancer deaths is higher in low- and middle-income countries 
due to constraint in resource and infrastructure thus it challenges the aim to improve 
breast cancer fallouts by early detection, diagnosis and treatment (Anderson et al., 
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2008). Moreover, poor health awareness and education, lack of screening programs 
because lacking of governmental support and insufficient funds, social barriers to early 
diagnosis and treatment due to low priority for women health issues in predominantly 
patriarchal developing societies, fear of loss of employment and the social taboo of 
cancers and misconceptions about cancer treatment and outcomes, lack of standardized 
treatment protocols with diversity of clinical practice, health care standards and 
infrastructure, and finally poor follow up data and the lack of mortality data (Tfayli et 
al., 2010).  
In high income countries such as United States, breast cancer is the most commonly 
diagnosed cancer among American women compared to other types of cancers such as 
lung and skin cancers (CDC, 2016). Approximately 252710 of estimated new cases for 
women will be diagnosed with invasive breast cancer and 40610 will be die due to 
breast cancer in 2017 (Figure 2.1) (Siegel et al., 2017). The prevalence of estimated new 
cases and estimated deaths for breast cancer in 2017 is increasing compared to 2016, 
where the estimated cases were 246660 and the estimated deaths were 40450 (Siegel et 
al., 2016). Breast cancer is increasing particularly in developing countries, where the 
majority of cases are diagnosed in late stages (WHO, 2017b). Ferlay et al. (2010) also 
stated that approximately 60% of breast cancer related deaths are occurring in low- and 
middle-income countries. 
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Figure 2.1: Ten leading cancer types for the estimated new cancer cases and deaths by 
sex, United States 2017 by Siegel et al. (2017).  
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In Malaysia, breast cancer is one of the most important undeniable non-communicable 
diseases that caused 13.56% of all death in 2015 (Ab Manan et al., 2016). The 
percentage of breast cancer is highest which is 17.7% (Figure 2.2) compared to other 
most common cancers in Malaysia such as colorectal and lung cancers (Ab Manan et 
al., 2016). It is also dominating the percentage of common cancers in females by 32.1% 
(Table 2.2) (Ab Manan et al., 2016; The Star Online, 2016). The incidence increases 
gradually from the age of 30 and peaks at 50 to 59 years old. The racial distribution is 
41% Chinese, 33% Malay and 26% Indian and almost half of the cases are already 
Stage II when diagnosed (The Star Online, 2016). This event happens due to the 
increase of growth and aging of the population as well as an increasing prevalence of 
established risk factors such as smoking, overweight, physical inactivity and changing 
reproductive patterns associated with urbanization and economic development (Ab 
Manan et al., 2016). 
  
	 12 
 
Figure 2.2: Percentage of ten most common cancers in Malaysia by Ab Manan et al. 
(2016). 
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Table 2.2: Ten most common cancer in females by Ab Manan et al. (2016). 
Sites Number Percentage (%) 
Breast 18206 32.1 
Colorectal 6047 10.7 
Cervix uteri 4352 7.7 
Ovary 3472 6.1 
Trachea, bronchus, lung 3193 5.6 
Lymphoma 2203 3.9 
Corpus uteri 2181 3.8 
Leukemia 2024 3.6 
Thyroid 1723 3.0 
Stomach 1447 2.6 
Others 11865 20.9 
TOTAL 56713 100.0 
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2.1.3 Signs and symptoms of breast cancer 
Signs and symptoms of the breast cancer may include formation of a new lump or mass. 
According to American Cancer Society (2016), usually, a painless and hard mass, which 
has irregular edges is more likely to be cancerous. Other possible symptoms of breast 
cancer such as a change in the breast shape, which is swelling of all or part of a breast, 
dimpling of the skin, having pain in the breast or nipple, nipple is turning inward 
(retraction), redness, thickening of the nipple or breast skin as well as having nipple 
discharge, which means the fluid comes out is other than breast milk (Healthline, 2017).  
2.1.4 Risk factors of breast cancer 
The risk factors for developing breast cancer including being a woman, increased in 
age, having a family history of breast cancer, radiation exposures and unhealthy 
lifestyles such as drinking alcohol and being overweight (obese) (Shah et al., 2014).  
Breast cancer in men is a rare disease and it accounts ~1% of all breast cancer cases 
(Rashid et al., 2017). However, men also can have breast cancer but it is usually most 
common in women compared to men due to less of estrogen and progesterone levels in 
men (Allen et al., 2013). Both of these hormones can promote growth of cancer cell in 
the breast. Allen et al. (2013) also stated that, breast cancer is 100 times common in 
women compared to men whereas American Cancer Society (2016) stated that breast 
cancer accounts for over 32% of all invasive cancers in women and only 1% in men.  
Increased of growth and aging of the population is also contributing in getting breast 
cancer. As a person increases in age, the risk of getting breast cancer is also high. Breast 
cancer is rarely found in people under 20 years old, but the incidence rates of the breast 
cancer is increasing and become significant after 50 years old (Allen et al., 2013). In 
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addition, invasive breast cancer is mostly found in women age 60 and older (Siegel et 
al., 2017). 
Women who have a close relative or family history of the breast cancer have higher risk 
of developing breast cancer (Colditz et al., 2012). Moreover, it is important to notice 
that women who have a first-degree relative; mother, sister or daughter have a double-
risk in getting breast cancer. Meanwhile, by having two first-degree relatives will 
increase women’s risk to have breast cancer about three-fold (ACS, 2016). 
Radiation exposure from various sources such as CT-scan and x-ray especially having 
radiation to the chest increases the risk of getting breast cancer (Henderson et al., 2010). 
Other than that, women who are having another type of disease such as Hodgkin’s 
disease are at higher risk to get breast cancer (Guibout et al., 2005). Besides that, 
radiation effects on development of breast cancer in females also been proved in Japan 
post nuclear attack on Hiroshima and Nagasaki (Preston et al., 2007). 
Alcoholic person has been claimed to have higher risk associated with breast cancer and 
the risk of getting breast cancer is directly proportional to the amount of alcohol 
consumption (Yip et al., 2006). Being physical inactive is also one of the risk factor 
contributing in breast cancer, where it can lead to overweight or obese (Wu et al., 
2013). Postmenopausal women are more common to be obese because during this time 
the ovaries stop making estrogen and in most of a woman, estrogen comes from fat 
tissue, thus, the estrogen level increased and the chance of having breast cancer is also 
increased (Lahmann et al., 2004; Ritte et al., 2012). 
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2.2 Cancer chemotherapy 
The word ‘chemotherapy’ is defined to any system in which chemical substances are 
used to treat a disease (Schnitzer and Hawking, 1964). The modern era of cancer 
chemotherapy began in the 1940s with the initial trial of chemical warfare known as 
nitrogen mustard during World War I (Gilman, 1963). Over past decades, 50 licensed 
drugs in the clinical practice was used for the management of malignant disease have 
been introduced (Fernando and Jones, 2015). The study of adjuvant chemotherapy is 
facilitated by the ability of combination chemotherapy to cure acute childhood leukemia 
and advanced Hodgkin’s disease in the 1960s and early 1970s, thus it prevailed 
pessimism about the ability of chemotherapy drugs to cure advanced cancers (DeVita 
and Chu, 2008).  
Chemotherapy drugs can induce apoptosis (programmed cell death), either by directly 
inhibiting DNA or by targeting key proteins required for cell division (Johnstone et al., 
2002). However, chemotherapy drugs can give toxic effects to normal cells (Fernando 
and Jones, 2015). In general, there are two types of chemotherapy drugs, where, they 
are classified by their cell cycle effects or by biochemical properties. Chemotherapy 
drugs that are in the same biochemical class have a similar mechanism of action (Table 
2.3). Meanwhile, by classifying them based on their cell cycle specificity is crucial 
because it gives consequences how drugs are schedule and combined to produce 
maximal effect (Fernando and Jones, 2015).  
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Table 2.3: Biochemical classification of chemotherapy drugs by Fernando and Jones 
(2015). 
Drug class Mechanism of action Examples 
Alkylating 
agents 
Impair cell function by forming covalent bonds 
on important molecules in proteins, DNA and 
RNA. Classified by their chemical structure 
and mechanism of covalent bonding. 
Platinums 
(cisplatin, 
carboplatin, 
oxaliplatin) 
nitrogen mustards 
(chlorambucil, 
melphalan) 
oxazophosphorines 
(cyclophosphamide, 
ifosfamide). 
Anti-
metabolites 
Structural analogues of naturally occuring 
metabolities involved in DNA and RNA 
synthesis. They either substitute for a 
metabolite that is normally incorporated in to 
DNA or RNA or compete for the catalytic site 
of a key enzyme. 
Pyrimidine 
analogues 
(gemcitabine, 5-
fluorouracil, 
capecitabine) anti-
folates 
(methotrexate, 
raltitrexed). 
Anti-tumour 
antibiotics 
Intercalate DNA at specific sequences, creating 
free radicals which cause strand breakage. 
Anthracyclines are products of the fungus 
Streptomyces, also have mechanism of action 
of topoisomerase I and II, required for the 
uncoiling of DNA required for DNA synthesis. 
Anthracyclines 
(doxorubicin, 
epirubicin), 
bleomycin, 
mitoxantrone. 
Topoisomerase 
inhibitors 
Topoisomerases are enzymes that control the 
3D structure of DNA. Topoisomerase I and 
Topoisomerase II are enzymes responsible for 
the uncoiling of DNA during replication. 
Topoisomerase I 
inhibitors 
(irinotecan, 
topotecan), 
	 18 
topoisomerase II 
inhibitors 
(etoposide). 
Tubulin 
binding drugs 
Vinca alkaloids bind to tubulin, and prevent the 
formation of the microtubule, which is 
important during mitosis, but also for cell 
shape, intracellular transport and axonal 
function. Taxoids prevents the disassembly of 
the microtubules, thereby inhibit normal 
function. 
Vinca alkaloids 
(vincristine, 
vinorelbine), 
Taxanes (paclitaxel, 
docetaxel). 
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In clinical practice, most of the combination chemotherapy consists of a few agents 
from various classes, thus there are several principles to achieve an effective 
combination chemotherapy including different phases of the cell cycle (Figure 2.3), 
which are targeted to achieve a maximal cell kill and there is less likelihood of 
resistance emerging (Fernando and Jones, 2015). Other than that, the combination of 
drugs that used should have action against the tumour and drugs which exert maximal 
effects are most preferred (Fernando and Jones, 2015). In order to achieve the most 
effective combination chemotherapy, the mechanism of action also should be distinct to 
grant addictive or synergistic effects (Fernando and Jones, 2015). In addition, the 
toxicities must have least overlapping to cut down the exposure of life threatening 
toxicity to a single organ system (Fernando and Jones, 2015).  
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Figure 2.3: Actions of chemotherapy agents on the cell cycle by Fernando and Jones 
(2015). 
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Despite of their successful in becoming one of the way of cancer treatment, the side 
effects of chemotherapy have been noticed and it is based on the specific agent, dose, 
route and schedule of administration and several patient factors, which may be known 
and unknown (Fernando and Jones, 2015). The most common adverse events that occur 
due to chemotherapy include neutropenia, stomatitis, mucositis, diarrhea, and emesis 
(Hauner et al., 2017). However, these adverse events can be considerable if the patients 
are carefully educating and monitor during treatment. The competence of chemotherapy 
can be enhanced by doing good prophylaxis, standardized management of toxicities and 
limit the doses where threshold is known for the late side effects of chemotherapy 
(Fernando and Jones, 2015; Hauner et al., 2017). 
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2.2.1 Tamoxifen 
Tamoxifen (Figure 2.4) is a non-steroidal anti-estrogen, which is the first targeted 
therapy using the tumor estrogen receptor (ER) as the target (Jordan, 2014). Usually, it 
is used to decrease the risk of early-stage, hormone-receptor-positive breast cancer after 
coming back from surgery (Breast Cancer, 2017). Moreover, tamoxifen is also used in 
treating the advanced-stage of breast cancer such as metastatic breast cancer and ductal 
carcinoma in situ (DCIS) (Breast Cancer, 2017).  
  
	 23 
 
Figure 2.4: Chemical structure of tamoxifen by National Cancer Institute (2017). 
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There are two types of targeted approaches to anti-estrogenic therapy. Firstly, tamoxifen 
and its metabolites anticipate the tumor ER and it is also can avoid estrogen-stimulated 
growth (Maximov et al., 2014). Secondly, an aromatase inhibitor (AI) inhibits the 
production of estrogen in postmenopausal patients, therefore, the AI is considered as an 
adjuvant treatment of choice for postmenopausal breast cancer patients (Maximov et al., 
2014). Generally, tamoxifen is given up to five years for longer therapy whereas a 
current recommendation for shorter therapy (standard therapy) is less than five years 
(Davies et al., 2013). However, these recommendations do not increase the 
effectiveness or increase of patients’ survival (Davies et al., 2013). 
Tamoxifen is one of the anti-neoplastic selective estrogen receptor modulators 
(SERMs), where it has specificity in tissue activities. SERM works by cutting off the 
response of estrogen in the breast tissue by adhering to the estrogen receptors in breast 
cells (Breast Cancer, 2017). The mechanism of tamoxifen begins when it completely 
inhibits the binding of estradiol to estrogen receptors, thus it blocks the receptor from 
binding to the estrogen-response element on DNA resulting in decreasing of DNA 
synthesis and cellular response to estrogen (NCI, 2017). The up-regulation of tamoxifen 
leads to the synthesis of transforming growth factor-ß (TGF-ß), a factor that constrains 
tumor cell growth. Moreover, tamoxifen is also can down-regulate a factor that 
stimulates breast cancer cell growth known as insulin-like growth factor-1 (IGF-1) 
(NCI, 2017). 
Although tamoxifen has a potential role as a chemotherapeutic drug in treating patients 
with breast cancer, it has been limited by the lack of selectivity and specificity as well 
as numerous of adverse effects (Sultana et al., 2003). Gynecological side effects such as 
endometrial carcinoma, premalignant endometrial changes, vaginal dryness and sexual 
